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Abstract: Primary vitreoretinal lymphoma (PVRL) or primary intraocular lymphoma, a 
subtype of primary central nervous system lymphoma, often masquerades as uveitis. The 
diagnosis of PVRL requires identification of lymphoma cells inside the eye, which is often 
challenging  due  to  the  frequent  necrosis  and  admixing  of  PVRL  cells  with  reactive 
lymphocytes.  Therefore,  detection  of  immunoglobulin  heavy  chain  (IgH)  and  T-cell 
receptor  (TCR)  gene  rearrangements  provide  molecular  diagnosis  of  B-  and  T-cell 
lymphoma, respectively. We retrospectively evaluated 208 cases with a clinical diagnosis 
of masquerade syndrome from 1998 to 2010. In 200 cases with molecular analyses using 
microdissection and polymerase chain reaction, we found that 110 cases had IgH gene 
rearrangement, 5 cases had TCR gene rearrangement, and 85 cases were negative for these 
two gene arrangements. The molecular data corroborated the cytopathological diagnoses of 
PVRL  and  uveitis  in  the  majority  of  cases.  Cytokine  above  the  detected  levels  in  the 
specimens were also measured in 80 of the 208 cases. A ratio of vitreous IL-10 to IL-6 
greater  than  1,  suggesting  PVRL,  was  found  in  56/80  cases;  53/56  had  the  correct 
diagnosis. A ratio less than 1, suggesting uveitis, was found in 24/80 cases; 17/24 correctly 
confirmed the diagnosis. Moreover, the molecular data corresponded well with the clinical 




course of the diseases. The sensitivity and specificity of these molecular biomarkers for the 
diagnosis of PVRL are higher than 95%. 
Keywords:  primary  vireoretinal  lymphoma;  biomarker;  immunoglobulin  heavy  chain;  
T-cell receptor; gene arrangement; microdissection; polymerase chain reaction 
 
1. Introduction  
Primary vitreoretinal lymphoma (PVRL), also known as primary intraocular lymphoma, is a subset 
of  primary  central  nervous  system  lymphoma  (PCNSL)  [1].  PVRL  initially  involves  the  vitreous, 
retina, subretinal space, and optic nerve with or without simultaneous CNS involvement [2,3]. The 
majority of PVRL is extranodal, non-Hodgkin, diffuse large B-cell lymphoma (DLBCL) [4]. Although 
rare,  T-cell  lymphoma  with  intraocular  involvement  has  also  been  reported,  usually  with  poor 
prognosis [5–7]. 
Clinically, PVRL often masquerades as uveitis, which is most commonly characterized by vitritis, 
presence of cells in the anterior chamber, and subretinal yellow infiltrates (Figure 1) [8–10]. Clinical 
manifestations, fundoscopic and ocular imaging (autofluorescence, fluorescein angiography and optic 
coherence tomography) often provide characteristic features of PVRL. Diagnosis of PVRL requires 
pathologic identification of atypical lymphoma cells from the vitreous or retina. Cerebrospinal fluid 
(CSF), aqueous humor, subretinal fluid, and intraocular tissues (such as chorioretinal tissue or iris) are 
also used for pathology [11]. However, the cytopathologic diagnosis is challenging because of the 
fragility and paucity of the atypical lymphoma cells in the vitreous [12]. Moreover, atypical lymphoma 
cells in the vitreous often admix with reactive lymphocytes, necrotic cells and debris, adding to the 
difficulty of diagnosis. Additionally, pathologic diagnosis can only determine the presence of tumor 
cells instead of identifying them as B- or T-cell lymphoma. 
Figure 1. Fundoscopy of a patient with primary vitreoretinal lymphoma (PVRL) showing 
multiple yellowish subretinal lesions and small areas of retinal necrosis. 




Monoclonal rearrangements of immunoglobulin heavy chain (IgH) and T-cell receptor (TCR) genes 
can be detected and these molecular techniques provide a reliable biomarker for lymphoma cells. The 
IgH gene in B lymphocytes is comprised of three highly variable complementarity determining regions 
(CDR), separated by four relatively conserved framework regions (FR) [13–15]. Among them, CDR3 
is the most variable region of the rearranged IgH gene and can be detected by several primers such as 
FR2A, FR3A, and CDR3 [8,16]. Similarly, TCR gene rearrangement, most commonly TCR gamma 
gene rearrangement, serves as a molecular marker of clonal expansion of T-cell lymphoma [5,17]. 
TCR gene rearrangement can be detected by primers such as TCR-gamma and TCR-CDR3 [18,19]. By 
using microdissection to obtain at least 15 atypical lymphoid cells and performing polymerase chain 
reaction (PCR), specific gene rearrangements can  be detected in these  specimens  from  lymphoma 
patients  [20].  Thus,  molecular  analysis  provides  a  useful  adjunct  to  the  diagnosis  as  well  as 
classification of PVRL. 
Interleukin-10 (IL-10) is regarded as a growth and differentiation factor for B lymphocytes [21]. 
The level of IL-10 is increased in the vitreous and CSF of patients with PCNSL [22–24]. IL-6, which 
is produced by a wide variety of cell types including inflammatory cells, is a marker of inflammatory 
diseases [25]. IL-6 is simultaneously measured in the same specimen in order to internally control for 
the dilution of the vitreous during sample collection. Previous studies have found that both elevated IL-10 
levels and a high IL-10 to IL-6 ratio in the vitreous are indicative of PVRL in many patients [22,23,26]. An 
IL-10 to IL-6 ratio greater than 1 is the most useful predictor of lymphoma. On the other hand, an  
IL-10 to IL-6 ratio of less than 1 suggests the presence of uveitis. The IL-10 to IL-6 ratio can be 
influenced by many factors, such as previous corticosteroids or immunosuppressive treatments and 
certain systemic diseases that may influence various cytokine productions, which limits its diagnostic 
power. However, significantly elevated IL-10 levels (>400 pg/mL in the undiluted vitreous) alone may 
also raise suspicion of intraocular lymphoma [24]. 
This study focuses on the molecular analysis of IgH and TCR gene arrangements as the biomarker 
of  the  B-  and  T-cell  PVRL  for  the  diagnosis  and  classification  of  PVRL.  The  diagnostic  value 
(including sensitivity, specificity, positive and negative predictive value, and efficiency) of molecular 
analysis, cytopathologic findings, and the IL-10 to IL-6 ratio are compared in patients with the clinical 
diagnosis  of  ocular  masquerade  syndrome  that  are  highly  suspected  of  PVRL.  Our  findings 
demonstrate that molecular results correlate well with the clinical course of PVRL and contribute to 
the clinical diagnosis and classification of PVRL. 
2. Results and Discussion  
2.1. Patient Demographics 
A total of 227 specimens from 214 patients clinically diagnosed with masquerade syndrome were 
identified  from  1998  to  2010  at  the  National  Eye  Institute,  National  Institutes  of  Health.  All  the 
patients involved are highly suspected of PVRL. Of these, there was one specimen per patient for  
203 patients and multiple specimens for 11 patients. Total pathologic specimens comprised of 175 
vitreous, 11 aqueous, 21 CSF, 5 subretinal fluid, 4 iris, 7 retina/chorioretina, 3 brain, and 1 orbital  
tissue (Table 1).  









Specimen Type (n = patients) * 
Number of 
Specimens 
1  203 
vitreous (164), aqueous (10), 
CSF (14), subretinal fluid (2), 
iris (3), retina/chorioretina (6), 
brain (3), orbital tissue (1) 
 
203 
2  9 
vitreous + iris (1), 
vitreous+chorioretina (1), 
vitreous + CSF (5), 
vitreous+subretinal fluid (2) 
 
18 
3  2 
vitreous + CSF + subretinal fluid (1), 
vitreous + CSF + aqueous (1) 
6 
Total  214  227 
* The number of patients who submitted each specimen type is indicated in parentheses.  
2.2. Clinical Findings 
Among 214 patients, PVRL was confirmed in 119 patients, and uveitis in 89 patients. In 6 patients, 
a  definitive  diagnosis  could  not  be  reached  due to  insufficient  specimen  for  cytological,  cytokine 
and/or molecular analysis (Table 2). Therefore, 208 patients with definitive diagnoses were included in 
the final analysis.  
Table 2. Demographics in patients of masquerade syndrome. 
  PVRL  Uveitis  Total 
Number  119 *  89  208 
Age (mean ± SD)  65.2 ± 12.4  65.8 ± 13.9  65.5 ± 13.1 
Gender (male:female)  1:1.2  1:1.8  1:1.4 
* Five of 119 patients were identified with T-cell lymphoma. 
The average age showed no statistical difference between PVRL and uveitis patients (65.2 ± 12.4 
vs. 65.8 ± 13.9, P = 0.60, Table 2). The gender distribution was not significantly different between 
PVRL and uveitic patients (1:1.2 vs. 1:1.8, P = 0.18, Table 2). 
The majority of patients (81.7%) did not have other systemic malignancies. Of the 38 patients who had 
systemic malignancies, most had lymphoma; only one patient had PVRL and systemic non-hematological 
tumor (Table 3). Interestingly, 13 uveitis patients also had hematological malignancies (11 lymphoma 
and 2 leukemia). 








with Systemic Malignancy 
Lymphoma  Leukemia  Other Malignancy 
PVRL  67  20  2  1 
PVRL + PCNSL  27  2  0  0 
Uveitis  72  11  2  0 
Uveitis + PCNSL  4  0  0  0 
Total  170  33  4  1 
2.3. Molecular Analysis 
Microdissection of the atypical lymphoid cells and PCR were performed for 200 of the 208 patients 
(Table 4). Among the 200 patients, 114 were diagnosed with PVRL and showed IgH (109 cases with 
B-cell lymphoma, Figure 2a) or TCR (5 cases with T-cell lymphoma, Figure 2b) gene rearrangements. 
In contrast, 85 of the 86 uveitic patients showed negative IgH or TCR gene rearrangements; only one 
uveitic patient had positive IgH gene rearrangement. 
Table 4. Molecular analysis. 
IgH/TCR Gene Rearrangements  PVRL  Uveitis  Total 
Positive   114  1  115 
Negative   0  85  85 
Total   114  86  200 
Sensitivity = 1.0 
Specificity = 0.99 
Positive predictive value = 0.99 
Negative predictive value = 1.0 
Test efficiency = 0.995 
Figure  2.  PCR  of  gene  rearrangements  in  two  patients  with  PVRL:  (a)  IgH  gene 
rearrangement of B-cell PVRL was detected using primer pairs of CDR3 and FR3A but not 
FR2A. (b) TCR gene rearrangement of T-cell PVRL was detected using primer pairs of 
TCR-gamma and TCR-CDR (Lane 1, vitreous specimen; Lane 2, negative control; Lane 3, 
positive control).  
   




2.4. Cytological and Pathological Findings 
Among the 208 patients who had defined diagnoses, 205 had specimens for cytological analysis  
to  identify  atypical  lymphoid  cells  (Figure  3).  Twenty-three  of  205  patients’  specimens  did  not  
have identifiable cells due to poor morphology. A total of 182 cases were included for cytological 
analysis (Table 5). 
Figure 3. Cytology of a patient with PVRL showing a large atypical lymphoid cell (arrow) 
with  large  nuclei,  prominent  nucleoli,  and  scanty  basophilic  cytoplasm  in  the  vitreous 
specimen (Giemsa, original magnification, ×640). 
 
Table 5. Cytological and pathological analysis. 
Atypical Lymphoid Cells  PVRL  Uveitis  Total 
Present  81  1 *  82 
Absent  19 
†  81  100 
Total   100  82  182 
Sensitivity = 0.81 
Specificity = 0.99 
Positive predictive value = 0.99 
Negative predictive value = 0.81 
Test efficiency = 0.890 
* There are less than 15 atypical lymphoid cells identified in the specimen and the majority of the 
lymphocytes are CD3 positive T cells in this case.  
†  The  specimens  contained  atypical  lymphoid  cells  with  poor  morphology,  which  are  highly 
suspected of lymphoma cells.  
2.5. Cytokine Analysis 
IL-10 and IL-6 analysis were performed in 118 of the 208 patients. Thirty-eight patients had below 




these patients. The IL-10 to IL-6 ratio was available for 80 patients and the results are listed in Table 6. 
The ratio was less than 1 in 7 PVRL patients, including 3 of the 5 T-cell lymphoma cases.  
Table 6. Cytokine analysis.  
IL-10 to IL-6 Ratio  PVRL  Uveitis  Total 
>1  53  3  56 
<1  7  17  24 
Total   60  20  80 
Sensitivity = 0.88 
Specificity = 0.85 
Positive predictive value = 0.95 
Negative predictive value = 0.71 
Test efficiency = 0.875 
All patients were treated based on the molecular diagnosis accordingly. Clinical follow-up on these 
patients also confirmed the diagnosis. Overall,  the  molecular technique  has the highest diagnostic 
value  in  PVRL  among  the  three  methods  analyzed  in  our  study  (Table  7).  Cytology  has  higher 
specificity and positive predictive value compared with cytokine analysis in PVRL patients. However, 
cytokine analysis has higher sensitivity and negative predicative value.  
Table 7. Comparison of the diagnostic value in molecular, cytological, and cytokine analysis. 
Diagnostic 
Method 









1  0.99  0.99  1  0.995 
Cytology  0.81  0.99  0.99  0.81  0.890 
IL-10/IL-6 ratio  0.88  0.85  0.95  0.71  0.875 
2.6. Discussion 
PVRL is a potentially fatal malignant disease and accurate diagnosis is of critical importance for 
prompt and appropriate intervention. The gold standard for PVRL diagnosis is detection of lymphoma 
cells in the retina and/or vitreous. Additionally, clinical manifestations and examinations are important 
for the diagnosis of PVRL. This study suggests that the molecular analysis of IgH and TCR gene 
rearrangements  using  microdissection  and  PCR  technique  has  the  highest  sensitivity,  specificity, 
predictive  value,  and  efficiency  for  the  diagnosis  of  PVRL,  when  compared  with  morphological 
identification of atypical lymphoid cells or IL-10 to IL-6 ratio analysis. Moreover, detection of IgH or 
TCR  gene  rearrangements  in  the  microdissected  atypical  lymphoid  cells  greatly  facilitates  the 
diagnosis  and  classification  of  PVRL.  The  molecular  analysis  correlates  well  with  the  clinical 
diagnosis  of  PVRL  and  can  be  used  as  reliable  biomarkers  for  the  diagnosis  and  classification  
of PVRL. 
PVRL usually masquerades as uveitis; thus, identification of lymphoma cells in the eye is required 
for  the  diagnosis  of  PVRL.  Typical  lymphoma  cells  are  characterized  by  large  nuclei,  prominent 




of normal, naive lymphocytes and may have irregular nuclear contours, a fine to coarse chromatin 
pattern and scanty basophilic cytoplasm [29]. Although PVRL cells have characteristic features, they 
are very fragile and easily degenerate in the specimen and even in the eye [8,12]. If the specimen is not 
promptly transported and/or carefully processed, most PVRL cells will show degeneration or may even 
become  necrotic. In this study,  12% of the  specimens did  not have  identifiable cells due to poor 
morphology, resulting in no diagnosis based on cytology alone. 
Although cytological analysis is critical for identifying tumor cells in PVRL, further classification 
of  the  cell  origin  of  lymphoma  cells  must  rely  on  immunophenotyping  using  techniques  such  as 
immunohistochemistry  or  flow  cytometry.  Immunohistochemistry  staining  of  the  B  cell  marker  
(e.g.,  CD19,  CD20,  lambda,  and  kappa)  and  T  cell  marker  (e.g.,  CD3)  help  differentiate  the 
monoclonality  of  lymphoma  cells.  Other  studies  have  reported  that  flow  cytometric 
immunophenotyping is a useful alternative to conventional diagnostic techniques. It refines cytological 
diagnosis  and  helps  in  the  classification  of  ocular  lymphoma  [30,31].  However,  flow  cytometric 
immunophenotyping requires relatively larger quantities of material and ocular specimens are often 
limited to very small amounts [31]. Thus, the paucity and fragility of the lymphoma cells in the eye 
restrict the application of immunophenotyping analysis for PVRL diagnosis and classification.  
PVRL cells show monoclonal rearrangement of IgH genes in B-cell lymphoma and TCR genes in 
T-cell lymphoma. This feature favors the molecular diagnosis and classification of lymphoma using 
microdissection to procure the atypical lymphoid cells and PCR to detect gene rearrangements in these 
cells. The antigen-binding sites of IgH and TCR molecules are encoded by sets of gene regions that 
include variable (V), diversity (D), and jointing (J) gene regions. The variable region undergoes gene 
rearrangements that increase the diversity of the immune receptor repertoire [17,32]. Among them, 
CDR3 in the V(D)J region of the IgH gene and TCR gamma in TCR gene are regarded as the most 
common sites of gene arrangement [5,8,16,17]. Because lymphoma usually derives from a single B or 
T cell, the tumor cell has the features of monoclonality. Thus, gene rearrangements of IgH and TCR in 
lymphoma cells serve as reliable biomarkers for the diagnosis and classification of PVRL. In this 
study, 114 cases of B-cell lymphoma are identified by molecular analysis using primers FR2A, FR3A, 
and/or CDR3 that cover the CDR3 region of the IgH gene in B-cell lymphoma. Five cases of T-cell 
PVRL  are  confirmed  by  the  positive  TCR  gene  arrangement  using  primer  TCR-gamma  and/or  
TCR-CDR3 in T-cell PVRL.  Only one uveitis case showed IgH gene rearrangement  in the CDR3 
region. No atypical lymphoid cells were found and a proinflammatory cytokine profile was measured 
in  this  specimen;  therefore,  the  molecular  data  alone  could  not  support  a  diagnosis  of  lymphoid 
neoplasm for this patient. The patient responded to anti-inflammatory therapy eventually. Though rare, 
molecular analysis could yield false positive results. 
Because  PVRL  cells  often  admix  with  many  reactive  lymphocytes  and  necrotic  cells, 
microdissection of at least 15 atypical lymphoid cells in individual specimens likely guarantees the 
purity  of  the  cell  source  for  PCR,  which  greatly  improves  the  accuracy  of  PVRL  diagnosis  via 
molecular analysis. By using microdissection and PCR, the sensitivity and specificity was nearly 100% 
in  patients  with  PVRL  in  our  study.  In  comparison,  others  reported  molecular  diagnosis  rates  of 
approximately 60% [33,34] and specificity around 0.64 in smaller case series [35]. In those molecular 




Vitreous biopsy remains the mainstay of PVRL diagnosis. Clinically, vitreous fluids are obtained by 
vitreous  aspiration  or  pars  plana  vitrectomy.  Our  results  showed  that  the  majority  of  submitted 
specimens (77%) were vitreous samples. Vitreous and aqueous fluids often have sparsely distributed 
tumor  cells  admixed  with  many  reactive  lymphocytes  and  debris,  which  make  it  difficult  for 
pathologists to differentiate tumor cells from inflammatory cellular contents. Moreover, lymphoma 
cells tend to have poor morphology due to prior corticosteroid treatment, mechanical damage during 
vitrectomy  and/or  prolonged  processing  procedure  [11,36,37].  All  of  these  reasons  make  PVRL 
diagnosis challenging.  Aqueous  is anatomically  farther away  from the  lymphoma  lesions than the 
vitreous simply because PVRL presents in the vitreous and retina. Although fewer PVRL cells are 
present in the aqueous than in the vitreous, lymphoma cells were found in 2 of the 4 PVRL cases with 
aqueous specimens. Of the same 4 PVRL cases, 3 had elevated IL-10 levels, which facilitated the final 
diagnosis of PVRL. Cassoux et al. also reported that cytokine measurements of the aqueous could be 
used as a good screening  method  for PVRL diagnosis [24].  Other  intraocular specimens,  such  as 
retina/chorioretina and subretinal fluids, are usually chosen when PVRL cells are absent in the vitreous 
samples [38–41]. In general, PVRL cells are easier to detect in the retina and subretinal space, where 
they initially reside. 
An IL-10 to IL-6 ratio greater than 1 in ocular fluid is highly suggestive of PVRL [26]. However, 
IL-10 secretion is affected by not only activated and malignant B cells, but also by other cells, such as 
Th1 and Th2 cells [42,43], and by many other factors, such as IL-12 levels [44]. In our study, 3 uveitic 
specimens (2 vitreous and 1 aqueous) showed elevated vitreous IL-10 levels and an IL-10 to IL-6 ratio 
greater than 1. Akpek et al. [45] also reported that the IL-10 to IL-6 ratio was greater than 1 in 8 of  
13 patients with non-neoplastic uveitis. In contrast, 7 (11.7%) PVRL cases showed a vitreous IL-10 to  
IL-6 ratio less than 1 in our study. Three of these were of T-cell origin and the low IL-10 level was 
compatible with the diagnosis of T-cell lymphoma [21]. Low IL-10 to IL-6 levels in B-cell lymphomas 
have also been reported in other studies [45,46]. This change may occur in patients who were in the 
early  stage  of  lymphoma  or  in  patients  who  have  been  previously  treated  with  corticosteroids  or 
immunosuppressive agents that influence the cytokine profile. Although an IL-10 to IL-6 ratio greater 
than 1 in the vitreous is suggestive of PVRL, this ratio cannot be used as the sole biomarker for PVRL 
diagnosis. However, cytokine analysis showed higher sensitivity and negative predicative value in this 
study, suggesting that it may serve as a useful adjunctive tool for screening patients suspected of PVRL.  
3. Experimental Section  
The medical records of 214 patients clinically diagnosed with masquerade syndrome and highly 
suspected  of  PVRL  were  reviewed  retrospectively.  All  cases  were  diagnosed  at the  National  Eye 
Institute  from  1998  to  2010.  The  study  was  approved  by  the  National  Eye  Institute  Institutional 
Review Board for human subjects and informed consent was obtained from all patients.  
The  protocol  for  specimen  processing  has  been  outlined  in  related  studies  [8,41].  Briefly,  the 
aqueous,  vitreous,  subretinal  fluid,  or  CSF  obtained  from  surgeries  was  processed.  The  fluid  was 
centrifuged at 1000 rpm. The supernatant was collected and IL-10 and IL-6 levels were measured 
using enzyme-linked immunosorbent assay. The sediment in the original tube was then resuspended 




cytospin slides were stained with Giemsa stain for cytology and molecular analyses. The biopsy tissue 
specimens  (including  iris,  retina/chorioretina,  brain,  and  orbital  tissue)  were  embedded  either  in 
paraffin  or  OCT  (Sakura  Finetek  USA  Inc.,  CA,  USA).  These  slides  were  routinely  stained  with 
hematoxylin and eosin for histology and molecular analyses.  
A minimum of 15 atypical cells were microdissected from the cytospin slides and digested with 
Proteinase K buffer. PCR and gel electrophoresis were used to detect the monoclonality of malignant 
B and T cells. The CDR3 of the IgH gene rearrangement in B-cell PVRL was detected by the 
32P 
labeled  primer  pairs  of  FR2A  (sense  5′-TGG  RTC  CGM  CAG  SCV  YCN  GG-3′  and  antisense  
5′-GGA TGG TAC CAA GCT TTG AGG AGA CGG TGA CCA-3′), FR3A (sense 5′-ACA CGG CYS 
TGT ATT ACT GT-3′ and antisense 5′-GGA TGG TAC CAA GCT TTG AGG AGA CGG TGA 
CCA-3′) and CDR3 (sense 5′-CCG GRA ARR GTC TGG AGT GG-3′ and antisense 5′-ATC CTG 
AGG AGA CGG TGA CC-3′). TCR gene rearrangement in the T-cell PVRL was detected by the 
32P 
labeled primer pairs of TCR-gamma (sense 5′-AGG GAT GTG TTG GAA TCA GG-3′ and antisense 
5′-CGT CGA CAA CAA GTG TTG TTC CAC-3′) and TCR-CDR3 (sense 5′-GAA AGG AAT CTG 
GCA TTC CGT CAG-3′ and antisense 5′-GAA GTT ACT ATG AGC YTA GTC CCT T-3′) [19]. 
After  gel  electrophoresis  and  autoradiography  overnight,  the  PCR  products  are  visible  by  using 
molecular imager (Bio-Rad Laboratories, CA, USA). 
The  student’s  t-test  was  used  to  calculate  numerical  data  and  the  chi-square  test  was  used  for 
categorical data. The analysis was performed using SPSS version 17.0 (SPSS Inc., IL, USA). P values 
less than 0.05 are considered statistically significant. The diagnostic value was recorded by sensitivity, 
specificity, positive and negative predictive value, and efficiency. 
4. Conclusions  
This study indicates that IgH and TCR gene rearrangements are reliable biomarkers for B- and  
T-cell PVRL, respectively. Using the molecular technique PCR to detect these gene rearrangements in 
microdissected atypical lymphoid cells has a higher diagnostic value than those from cytology and 
cytokine analyses. Although identification of intraocular tumor cells remains the gold standard for 
PVRL  diagnosis,  molecular  analysis  of  DNA  obtained  by  PCR  provides  valuable  supporting 
diagnostic  data,  especially  in  specimens  with  a  limited  number  of  cells  and/or  those  with  poor 
morphology.  The  accuracy  of  the  molecular  analysis  depends  largely  on  the  combination  of 
microdissection and PCR, which allows for selection of individual atypical lymphoid cells and ensures 
detection of the monoclonal characteristics of lymphoma cells.  
Through identification of specific IgH and TCR gene arrangements, molecular analysis contributes 
to further classification and confirmation of PVRL with only a small  number of  lymphoma cells, 
whereas routine cytological and cytokine analyses may not be able to provide such information from 
small specimens. Because B- and T-cell lymphomas respond differently to certain therapeutic agents 
such as Rituximab (monoclonal anti-CD20 antibody), which is effective in B-cell lymphoma [47], 
oncologists can choose the most effective targeted treatment for each individual PVRL patient based 
on specific lymphoid cell origins. 
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